Friday, November 20, 2026

NexusIgnite Plans Sovereign AI Cloud in Jordan, Starting With Its Universities

  


(BUSINESS WIRE)--NexusIgnite today announced plans for a sovereign AI cloud in Jordan. NexusIgnite’s Jordanian operating subsidiary will run it, and it is designed to initially serve up to five of the country’s universities. The platform is planned on AMD Instinct™ GPUs and Spectro Cloud’s PaletteAI platform. Service is targeted for 2027, subject to final agreements.


The platform is designed to keep research data, models, and workloads inside Jordan, under Jordanian operation. At the initial deployment, it will put AI compute in the hands of 200 university researchers. That is work that would otherwise run on infrastructure outside the country. In partnership with Jordan’s Ministry of Digital Economy and Entrepreneurship (MoDEE), NexusIgnite is also inviting other universities to take part as the platform grows.


“Jordan’s researchers shouldn’t have to send their work out of the country to use serious AI compute,” said Greg Forrest, Chief Executive Officer of NexusIgnite. “We’re building a cloud that keeps that work and its data in Jordan, run by our Jordanian subsidiary. We’re starting with the universities because that’s where the country’s AI talent is grown, and we expect the platform to grow with them.”


“This initiative marks an important step in strengthening Jordan’s sovereign AI capabilities and advancing its digital economy,” said Eng. Sami Smeirat, Minister of Digital Economy and Entrepreneurship. “By providing advanced AI computing infrastructure within the Kingdom, we are enabling Jordanian universities and researchers to conduct cutting-edge research, develop innovative AI solutions, and build local expertise, while ensuring that research data remains within Jordan. It also reflects our commitment to creating an enabling environment for innovation and positioning Jordan as a regional hub for advanced technologies.”


“With PaletteAI, Jordan will have control of its AI infrastructure from metal to token,” said Tenry Fu, co-founder and CEO of Spectro Cloud. “The full AMD stack will run in-country, managed, through a single platform, so universities can put AI to work on their own research while their data stays at home. And as demand grows, NexusIgnite will be able to scale capacity without increasing operational complexity.”


About NexusIgnite


NexusIgnite builds sovereign AI infrastructure for governments, universities, and regulated organizations that need AI compute to stay under their own control. The company designs in-country, AMD-based AI environments so customers can run AI workloads while their data stays inside their borders. NexusIgnite is headquartered in Austin, Texas, with a subsidiary in Dubai. Learn more at nexusignite.com.


About the Ministry of Digital Economy and Entrepreneurship (MoDEE)


The Ministry of Digital Economy and Entrepreneurship (MoDEE) leads Jordan’s digital transformation and works to advance the Kingdom’s digital economy and entrepreneurship ecosystem. The Ministry develops policies and initiatives to strengthen digital infrastructure, enhance digital skills, expand digital government services, foster innovation and entrepreneurship, and attract local and international technology investments, in partnership with the public and private sectors. Through these efforts, MoDEE aims to position Jordan as a competitive regional and international player in the digital economy.


About Spectro Cloud


Spectro Cloud helps platform teams and cloud providers modernize and manage infrastructure for the AI era without adding more tools or operational complexity. With PaletteAI, enterprises, public sector organizations, neoclouds and sovereign clouds can build, deploy, manage, govern and scale full-stack environments across VMs, Kubernetes, edge, regulated and air-gapped locations, and AI infrastructure. PaletteAI helps teams start quickly with Launchpads (turnkey, locally managed solutions for urgent outcomes such as VM modernization, token cost control and edge operations), then scale into centralized lifecycle management, governance and fleet operations on the same platform. Learn more at spectrocloud.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261119060732/en/



Permalink

https://aetoswire.com/en/news/54643430


Contacts

Media contacts

NexusIgnite: pr@nexusignite.com

Spectro Cloud: pr@spectrocloud.com

Gradiant Doubles Down on Water for AI, Forms Entropy International for Its Emerging Technologies

  


alkaLi (lithium recovery), ForeverGone (PFAS destruction) and Turing (AI for water) each with a dedicated team. Gradiant's core operating business is on track for about $150 million of EBITDA in 2027.


(BUSINESS WIRE) -- Gradiant, the world's first water-tech unicorn, today announced that its core operating business will focus on water for AI infrastructure. To support this, Gradiant has formed Entropy, a new platform that will build and scale the company’s emerging technologies, where each will have a dedicated team and runway.


A focused operating business, built for the AI economy

More than 90% of Gradiant’s core operating business now serves the AI economy, including semiconductor fabs, data centers, and the power and industrial plants that support them. The business is on track for about $150 million of EBITDA in 2027, with EBITDA above 20% of revenue. Its order backlog already covers most of expected 2027 earnings and about 35% of 2028. EBITDA has tripled from 2024 to 2026 and is on track to more than double again in 2027. That is a growth rate without precedent in the water industry.


Entropy: dedicated teams for the next wave

Entropy brings together Gradiant's emerging technologies, each led by a focused team:


alkaLi recovers lithium and critical minerals from brines and wastewater.


ForeverGone destroys PFAS, the "forever chemicals," rather than moving them from one place to another.


Turing, which Gradiant spun off in 2023, applies artificial intelligence to how water plants are run.


Other early-stage technologies will join over time. Entropy remains part of the Gradiant group. It will pursue these opportunities with a long-term horizon and concentrate investment on the few technologies that can reshape their markets.


"AI runs on chips, and chips run on water," said Prakash Govindan, Co-Founder and CEO of Gradiant. "Our operating business has become the water layer of the AI economy, and it deserves our full focus. alkaLi, ForeverGone and Turing each address a huge market of their own. Entropy gives them the teams and the focus to lead it."


"Lithium, PFAS and AI for water each need a different kind of runway," said Anurag Bajpayee, CEO of Entropy. "Giving them dedicated teams lets every part of Gradiant move faster."


Customers will see no change. Their teams, contacts and projects stay the same.


About Gradiant

Gradiant is the Water Layer of the AI Economy. Founded at MIT and headquartered in Boston, Gradiant builds the water and wastewater infrastructure behind AI's build-out, from chips and data centers to the energy and industries that depend on them. As AI demand accelerates, water is becoming the resource that determines what can be built. Gradiant's technologies reduce what industry withdraws, reclaim what it would waste, and renew clean water to nature, with more than 3,000 treatment plants built across 92 countries. Learn more at gradiant.com.


This release contains forward-looking statements, including expected financial results, which involve risks and uncertainties. Actual results may differ.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261119142764/en/



Permalink

https://aetoswire.com/en/news/1911202659219


Contacts

Corporate Contact

Felix Wang

Gradiant, Global Head of Marketing

fwang@gradiant.com

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back


 LOS ANGELES - Thursday, 19. November 2026 AETOSWire Print 



Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages


(BUSINESS WIRE) -- Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow.


Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game.


Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout.


PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally required paying to reach them again. Meanwhile, direct web sales have become a major revenue channel. Still, building and maintaining a separate web store or another app placement for every title is not practical for many studios, especially those with large back catalogs.


“A game shouldn’t only exist where a studio pays to reach players,” said Chris Hewish, President of Xsolla (USA), Inc. “Xsolla Player and Xsolla Pages put it on two more platforms, with quests, rewards, and offers giving players more ways to engage. Anyone can build a web page. What's hard is knowing which partner makes sense for a game and which offer fits each market. Xsolla Player and Xsolla Pages help studios with that.”


With Xsolla Player, gamers browse PC, web, and cloud games, start them with one click, and see live quests that highlight what to play next. Rewards are available for activities such as signing in, completing onboarding, launching a game for the first time, and finishing quests, and studios can also add their own quests and return-to-play rewards. Eligible items land in the player’s Backpack and carry over from one session to the next, while games and their available offers remain visible as players browse other titles.


Xsolla Pages gives each game a storefront on the web without the overhead of building one. Pages are built from a studio's existing catalog, and developers decide what each one sells, how it looks, and which markets it serves. Every page includes:


Search-ready setup. Search tags and social previews are set up, and page speed is checked, before each page goes live.


Backpack rewards. In-game items and perks that players keep in their Backpack, subject to the game’s terms, and use in-game.


Direct checkout. Purchases run on Xsolla's Merchant of Record infrastructure across 200+ geographies, with access to 1,000+ local payment methods and support for local payment and tax requirements.


Xsolla Pages is available to developers of any size, from studios with a single game to publishers with thousands of titles, for new releases and back catalog alike. More than 1,500 game teams already work with Xsolla.


Studios can learn more about Xsolla Player and get started with Xsolla Pages.


Readers can also complete a short Xsolla Quest at: xsolla.pro/p3-quest


What is Xsolla Quest? Xsolla Quest lets people complete a few simple steps on an Xsolla page to receive an item.


About Xsolla


Xsolla (USA), Inc. is a global commerce company that builds and provides all the things developers need to launch, grow, and monetize video games. Headquartered in Los Angeles, California, the company supports studios of every size, from indie to AAA, with solutions across direct-to-consumer commerce, intelligent payments, entertainment-based IP, and player engagement products. Xsolla helps developers fund, distribute, market, and monetize their games at scale. Trusted by more than 70% of the top 100 highest-grossing games, Xsolla operates as the merchant of record across 200+ geographies with access to 1,000+ local payment methods worldwide. Grounded in a deep belief in the future of video games, Xsolla is resolute in bringing opportunities together and unlocking growth for creators everywhere.


For more information, visit xsolla.com.


Xsolla Player and Xsolla Pages are offered by Xsolla (USA), Inc. (“Xsolla”). Rewards, in-game currency, badges, and Xsolla Points have no cash value and cannot be exchanged for cash or cryptocurrency. In-game currency can be used only as permitted by the game that issues it. Partner-funded offers, including any cashback or installment plans, are provided by third parties and subject to their terms. Rewards and offers are available only in supported territories.


© 2026 Xsolla (USA), Inc. All rights reserved.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261119175727/en/



Permalink

https://www.aetoswire.com/en/news/1911202659222


Contacts

Media Contact for Xsolla (USA)

Derrick Stembridge

Vice President of Global Public Relations, Xsolla

d.stembridge@xsolla.com

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

  


Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference

Mangaciclanol was well tolerated in the Phase 2 stage, with no safety concerns identified following its administration

Mangaciclanol has received FDA Fast Track designation, recognizing its potential to address significant unmet patient needs; approximately 65 million gadolinium-enhanced MRI procedures are performed each year

GE HealthCare to present preliminary Phase 2 results at RSNA 2026 (Industry Expert Theater)

 


(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is because of their potential to address concerns with gadolinium-based contrast agents around retention in the body, supply chain resiliency, and the environment. This milestone comes seven months after the first patient was dosed at Mayo Clinic in April 2026, and builds on Phase 1 results showing the agent was well tolerated.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119117575/en/


The Phase 2 stage of the adaptive Phase 2/3 trial design is a dose-finding study in adult patients with known or highly suspected lesions referred for contrast-enhanced MRI of the central nervous system. Participants received both mangaciclanol and gadobutrol, a gadolinium-based agent, with their images compared side by side by blinded independent readers. The primary endpoint, overall diagnostic preference, was met, with diagnostic preference similar between mangaciclanol and gadobutrol. Lesion visualization and quantitative imaging findings were generally similar, and mangaciclanol was well tolerated, with no safety concerns identified following its administration. Safety will continue to be evaluated in Phase 3. LUMINA is being conducted at clinical sites in the United States, Europe and Asia.


Dr Robert J. McDonald, M.D., Ph.D., neuroradiologist at Mayo Clinic, U.S., and one of the principal investigators of the LUMINA study, said, "For years, clinicians and patients have asked whether we can achieve the diagnostic confidence of gadolinium without the concerns around tissue retention and nephrogenic systemic fibrosis risk. These Phase 2 results are an important step toward answering that question. Seeing a manganese-based agent perform this well under blinded comparison with an established gadolinium agent is encouraging, and I look forward to what Phase 3 will show across a broader range of patients."


Kevin O’Neill, President & CEO of Pharmaceutical Diagnostics (PDx), GE HealthCare, said, “These positive Phase 2 results support dose selection for Phase 3, which will further evaluate the efficacy and safety of mangaciclanol-enhanced MRI for detecting and characterizing lesions of the central nervous system and body. As aging populations and the rising burden of chronic disease drive demand for imaging, we continue to invest in our contrast media portfolio and in what comes next. Manganese-based contrast agents have the potential to transform the MRI market, helping meet the evolving needs of clinicians and patients.”


Approximately one-third of global MRI procedures require a contrast agent,1 and around 65 million contrast-enhanced procedures are performed globally each year using GBCAs as the current standard of care.2 Unlike gadolinium, manganese is an endogenous element, present in our food, and naturally occurring and autoregulated in the body. Mangaciclanol's macrocyclic "cage-like" structure is designed to minimize the possibility of retention in the body. Gadolinium is a rare-earth metal largely dependent on mining and processing infrastructure in China, whereas manganese is an essential element abundantly available from multiple countries. Furthermore, as manganese is naturally found in water sources, MBCAs could reduce environmental concerns associated with excreted contrast agents.


Mangaciclanol has received Fast Track designation by the U.S. Food and Drug Administration (FDA), which expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs. Mangaciclanol is an investigational agent and is not currently approved for use by the FDA or any other regulatory authority. Its safety and efficacy have not been established.


GE HealthCare’s PDx segment is a global leader in imaging agents used to support 140 million patient procedures per year globally,3 equivalent to four procedures every second. For more than 40 years, GE HealthCare contrast media has been routinely used across MR, X-ray, CT and ultrasound to enhance clinical images and support diagnosis.


GE HealthCare will present preliminary Phase 2 trial results with clinical images, at RSNA in McCormick Place, Chicago, on Tuesday 1 December 12:00-13:00 at the Industry Expert Theater in South Hall A.


References:


Contrast Agents of Magnetic Resonance Imaging and Future Perspective. Nanomaterials. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10343825/

Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media. Investigative Radiology. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12871431/

GE HealthCare press release: GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand

About GE HealthCare Technologies Inc.


GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.


GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.


Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.


Forward-Looking Statements


This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction including the financial performance of the business, industry positioning, and GE HealthCare Technologies Inc.’s (“the Company’s”) business, products, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261119117575/en/



Permalink

https://aetoswire.com/en/news/54643994


Contacts

 

GE HealthCare Media Contact:

Polly Beaumont

M +44 7345 776251

polly.beaumont@gehealthcare.com

AMINA Bank يوسّع نطاق خدمات التحصيص ليشمل 10 أصول رقمية، مع إضافة عملتي SUI وNEAR



 يمكن أيضًا استخدام الأصول المرهونة للتخزين المؤهلة كضمان لحلول الإقراض التي تقدمها AMINA، مما يتيح للعملاء تعظيم عوائدهم مع الاحتفاظ بالحيازة الكاملة لأصولهم

(BUSINESS WIRE)-- أعلن AMINA Bank، وهو بنك سويسري متخصص في الأصول المشفرة، خاضع لرقابة الهيئة السويسرية للرقابة على الأسواق المالية (FINMA) ويتمتع بحضور عالمي، عن إضافة عملتي SUI وNEAR إلى خدماتها المرهونة للتخزين. وكان كلا الأصلين متاحًا بالفعل على منصة AMINA لخدمات الحفظ والتداول. وبإضافة هذين الأصلين، يرتفع إجمالي عدد الأصول الرقمية التي يمكن للعملاء إيداعها في خدمة التخزين لدى بنك AMINA إلى 10 أصول، ليقدم بذلك أشمل مجموعة من خدمات تخزين الأصول الرقمية بين البنوك الخاضعة للرقابة التنظيمية في سويسرا.

يمكن أيضًا استخدام الأصول المرهونة للتخزين المؤهلة لدى بنك AMINA كضمان للاستفادة من حلول الإقراض التي يقدمها البنك. ويتيح ذلك للعملاء الحصول على السيولة النقدية بضمان أصولهم المرهونة للتخزين، مع مواصلة الاستفادة من المكافآت التي توفرها البروتوكولات، وتحقيق عوائد تراكمية من خلال الجمع بين خدمتي التحصيص والإقراض، وكل ذلك في إطار علاقة واحدة خاضعة للرقابة التنظيمية.

 صرَّح Myles Harrison، الرئيس التنفيذي للمنتجات في AMINA، قائلاً: "ترتكز خدمات التحصيص التي نقدمها على مبدأ أساسي لا ينبغي التنازل عنه تحت أي ظرف، وهو: مفاتيحك وأصولك ومكافآتك ملك لك. ويظل كل أصل رقمي مرهون للتخزين محفوظًا لدى بنك AMINA، مع فصله بالكامل عن الميزانية العمومية للبنك، بما يتوافق مع اللوائح المصرفية السويسرية. كما نتيح لعملائنا إمكانية استخدام أصولهم المرهونة للتخزين كضمان للحصول على منتجات القروض التي نقدمها. إن هذا التكامل المميز بين الخدمتين يحوّل الأصول التي تظل عادةً غير مستغلة إلى أصول فاعلة".

 في إطار نموذج التحصيص غير القائم على نقل الحيازة الذي يعتمده بنك AMINA، لا تُتاح المفاتيح الخاصة لأي أطراف خارجية تحت أي ظرف. كما حصلت خدمات الحفظ الرقمي التي يقدمها البنك على تقرير تدقيق وفق معيار ISAE 3402 من النوع الثاني، فضلاً عن إمكانية استفادة الأصول المرهونة للتخزين من التغطية التأمينية التي يوفرها كل من مزودي خدمات التأمين من الأطراف الخارجية وAMINA Bank نفسه.
أصبحت خدمة التحصيص لعملتي SUI وNEAR متاحة الآن عبر الخدمات المصرفية الإلكترونية لبنك AMINA، أو من خلال التواصل مباشرةً مع مدير العلاقات المخصّص.

 *بيان إخلاء المسؤولية: يُعدّ هذا الموقع الإلكتروني مادةً إعلانية وتسويقية بالمعنى المقصود في المادة 68 من قانون الخدمات المالية السويسري (FinSA) والمادة 95 من اللائحة التنفيذية لقانون الخدمات المالية السويسري (FinSO). في حال الإعلان عن أي منتجات، يمكن الاطلاع على مستندات المنتجات ذات الصلة، متى كانت مطلوبة أو متاحة، عبر موقعنا الإلكتروني، أو الحصول عليها مجانًا عند الطلب. تخضع أي معلومات أو مستندات إضافية تُتاح لأغراض غير تسويقية للشروط والأحكام المحددة المطبقة على هذه المواد. تُقدَّم جميع المعلومات والمستندات الواردة في هذا الموقع الإلكتروني لأغراض إعلامية فقط. AMINA Bank AG هو بنك سويسري مرخّص وخاضع لرقابة الهيئة السويسرية للرقابة على الأسواق المالية (FINMA). AMINA مرخصة وتخضع للرقابة التنظيمية في سويسرا. وقد لا تكون المنتجات والخدمات الموضحة في هذا الموقع الإلكتروني مسجّلة أو معتمدة أو مطروحة أو متاحة في جميع الولايات القضائية، كما قد تخضع لقيود قانونية وتنظيمية. لا يُعدّ أيّ مما يرد في هذا الموقع الإلكتروني مشورةً استثمارية أو قانونية أو ضريبية أو أي نوع آخر من المشورة المهنية. لا يُشكّل هذا الموقع الإلكتروني عرضًا أو طلبًا أو توصيةً أو دعوةً لشراء أي أداة مالية أو بيعها، كما لا يُعدّ مشورةً مالية في أي ولاية قضائية تكون فيها مثل هذه الأنشطة غير قانونية. تنطوي الاستثمارات والأدوات المالية على مخاطر، بما في ذلك احتمال خسارة رأس المال. وقد تحتوي هذه المخاطر على مخاطر السوق والسيولة وأسعار الصرف والطرف المقابل والمخاطر التشغيلية، فضلًا عن مخاطر الأصول الرقمية أو مخاطر التكنولوجيا، حيثما ينطبق ذلك. ينبغي اتخاذ أي قرار استثماري فقط بعد مراجعة مستندات المنتج ذات الصلة والحصول، عند الاقتضاء، على مشورة مستقلة من جهة مختصة. قد لا تكون منتجات AMINA وخدماتها ومعلوماتها وموادها الواردة في هذا الموقع الإلكتروني متاحة أو معروضة أو موزعة للمقيمين في بعض الولايات القضائية. يتحمّل المستلمون مسؤولية التحقّق من أي قيود قانونية أو تنظيمية أو قيود على البيع تكون سارية في ولايتهم القضائية، والالتزام بها. لمزيد من المعلومات، يُرجى الرجوع إلى الشروط والأحكام المعمول بها لدى AMINA أو إلى قيود البيع السارية على المنتجات أو الخدمات المعنية.

 نبذة عن AMINA — للخدمات المشفَّرة. المعاملات المصرفية. الخدمات المبسَّطة.

تأسست شركة AMINA Bank AG في أبريل 2018 ويقع مقرها في تسوغ، سويسرا، وهي تُعدُّ من الجهات الرائدة في صناعة البنوك الرقمية المتخصصة في الأصول المشفَّرة. في أغسطس 2019، حصلت AMINA Bank AG على رخصة العمل المصرفي وتداول الأوراق المالية السويسرية من هيئة الإشراف على الأسواق المالية السويسرية (FINMA). في فبراير 2022، حصل فرع شركة AMINA Bank AG في سوق أبوظبي العالمي (ADGM) على تصريح تقديم الخدمات المالية من قِبل هيئة تنظيم الخدمات المالية (FSRA) التابعة لـ ADGM. وفي نوفمبر 2023، حصلت شركة AMINA (Hong Kong) Limited على تراخيص النوع الأول (التعامل في الأوراق المالية)، والنوع الرابع (تقديم الاستشارات حول الأوراق المالية)، والنوع التاسع (إدارة الأصول) من هيئة الأوراق المالية والعقود الآجلة ("SFC"). في أكتوبر 2025، تمت الموافقة على ترخيص النوع 1 لشركة AMINA ليشمل أيضًا خدمات التعامل بالأصول الرقمية للمستثمرين المحترفين ضمن الإطار التنظيمي للأصول الرقمية في هونغ كونغ. وفي أكتوبر 2025 أيضًا، حصلت AMINA (Austria) AG ("AMINA EU") على ترخيص مزوّد خدمات أصول العملات المشفَّرة (CASP) من هيئة الأسواق المالية النمساوية ("FMA") بموجب إطار MiCAR لتنظيم الأصول الرقمية.

كما صنّف تقرير CVVC Global وCB Insights بنك AMINA كواحد من أفضل 50 شركة في منظومة البلوكتشين العالمية. وفي عام 2025، حاز بنك AMINA على "جائزة الابتكار المؤسسي للأصول الرقمية للعام" خلال حفل Hedgeweek® Global Digital Assets Awards 2025. وحصل بنك AMINA مؤخرًا على تكريم ضمن جوائز PWM Wealth Tech Awards التابعة لـ FT Live، حيث نال جائزة "أفضل بنك رقمي مبتكر — البنوك الخاصة".

 لمعرفة المزيد عن AMINA، تفضَّل بزيارة www.aminagroup.com.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20261118756435/en



جهات الاتصال